Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 11, 2020 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020

NORCROSS, Ga., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes,...
December 04, 2020 16:17 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Inc. Recaps Results of Annual Meeting of Stockholders Presentation

NORCROSS, Ga., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the passing of the two...
December 01, 2020 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics to Webcast Corporate Update on December 3, 2020 after Annual Meeting of Stockholders

NORCROSS, Ga., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will...
November 09, 2020 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020

Innovative Phase 2b/3 NASH-RX Trial in NASH Cirrhosis Initiated Board Member Joel Lewis Assumes CEO Role – Board Adds Two New Highly Accomplished Professionals NORCROSS, Ga., Nov. 09, 2020 ...
September 29, 2020 12:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today

NORCROSS, Ga., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that the Company will host...
September 22, 2020 08:04 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020

NORCROSS, Ga., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the Company...
September 10, 2020 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020

NORCROSS, Ga., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will...
September 02, 2020 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Appoints Joel Lewis as Chief Executive Officer

Dr. Harold Shlevin retires as CEO, transitions to role of scientific and business consultant and will remain on the Board Board strengthened in scientific expertise with addition of Dr. Elissa...
August 10, 2020 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2020, and Provides Business Update

NORCROSS, Ga., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...
June 30, 2020 09:05 ET | Source: Galectin Therapeutics Inc.

UPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis

Clinical trial for patients with NASH cirrhosis who have the highest need for effective therapy Belapectin has previously shown ability to prevent the development of esophageal varices in this...